Blank, Christian U.

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 5,887

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,839

B cells and tertiary lymphoid structures promote immunotherapy response

Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 2,731

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science

Gut microbiota and healthBacterial Cancer Therapy

Cited by 2,464

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., Matos, C., Bruss, C., Klobuch, S., Peter, K., et al. (2016) · Cell Metabolism

Cancer, Hypoxia, and MetabolismCancer Immunotherapy and Biomarkers

Cited by 2,039

Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., et al. (2018) · New England Journal of Medicine

Cutaneous Melanoma Detection and ManagementCancer Immunotherapy and Biomarkers

Cited by 1,906

Defining ‘T cell exhaustion’

Blank, C. U., Haining, W. N., Held, W., Hogan, P. G., Kallies, A., Lugli, E., Lynn, R. C., Philip, M., Rao, A., Restifo, N. P., et al. (2019) · Nature Reviews Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,603

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,159

Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma

Li, H., van der Leun, A. M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A. C. J., van den Braber, M., Rozeman, E. A., Haanen, J. B. A. G., Blank, C. U., et al. (2019) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 1,101

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Liu, D., Schilling, B., Liu, D., Sucker, A., Livingstone, E., Jerby-Arnon, L., Zimmer, L., Gutzmer, R., Satzger, I., Loquai, C., et al. (2019) · Nature Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 1,039

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., et al. (2014) · Nature

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 888

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 880

PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 772

The “cancer immunogram”

Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 748

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 697

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Ascierto, P. A., Schadendorf, D., Berking, C., Agarwala, S. S., van Herpen, C. M., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., St-Pierre, A., et al. (2013) · The Lancet Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 640

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

Müller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., Kong, X., Possik, P. A., Cornelissen-Steijger, P. D. M., Foppen, M. H. G., et al. (2014) · Nature Communications

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 639

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 589

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 541

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 537

Immune resistance orchestrated by the tumor microenvironment

Gajewski, T. F., Meng, Y., Blank, C., Brown, I., Kacha, A., Kline, J., & Harlin, H. (2006) · Immunological Reviews

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 437

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 380

PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis

Mühlbauer, M., Fleck, M., Schütz, C., Weiss, T., Froh, M., Blank, C., Schölmerich, J., & Hellerbrand, C. (2006) · Journal of Hepatology

Cancer Immunotherapy and BiomarkersLiver Diseases and Immunity

Cited by 378

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers

Hadrup, S. R., Bakker, A. H., Shu, C. J., Andersen, R. S., van Veluw, J., Hombrink, P., Castermans, E., thor Straten, P., Blank, C., Haanen, J. B., et al. (2009) · Nature Methods

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 306